A Paradigm-Shifting Breakthrough: The "Cryo-Stasis" Framework Enables Low-Toxicity Vitrification of Small-Diameter Arterial Grafts
Release time:
2026-08-10
In cardiovascular reconstruction, small-diameter arterial grafts (<6 mm) remain a persistent clinical conundrum. While vitrification averts ice crystal lancing, its reliance on high-concentration cryoprotectants often inflicts osmotic shock and chemical toxicity during unloading, compromising tissue integrity before implantation. Recently, a team led by Prof. Zhao Gang—Chairman of the Expert Committee at YinFeng Cryogenic Institute and researcher at the University of Science and Technology of China—proposed the concept of "Cryo-Stasis" in Materials Today Bio. They engineered the CTX-RYST low-toxicity vitrification system, slashing the stenosis rate to a mere 3.5% after 42 days in rat transplant models—a figure nearly identical to that of fresh vessels. This study charts a new course for the long-term preservation of complex tissues.
The Underappreciated "Unloading Injury"
Prevailing dogma held that higher cryoprotectant concentrations inevitably escalated chemical toxicity, driving research toward concentration reduction. However, through real-time cellular monitoring, Prof. Zhao’s team uncovered a counterintuitive reality: the peak of cell death occurred not during loading, but surged dramatically during the removal of concentrated protectants. This reveals that drastic osmotic fluctuations constitute a critical injury window, shifting the focus from mere "concentration" to the kinetics of exposure.
Consequently, the team pivoted their strategy from "simply lowering concentration" to "enhancing cellular osmotic tolerance + drastically shortening unloading duration." This cognitive shift provided a novel target for subsequent technological design.
Rebalancing Act: The CTX-RYST Protocol
The team developed a comprehensive CTX-RYST system anchored by two synergistic innovations:
Composite Ice Inhibitor (CTX): By screening low-dose components such as polyvinyl alcohol, trehalose, and L-proline, the team leveraged intermolecular synergy to suppress ice nucleation while bolstering cellular resilience against hyperosmotic stress. Cryomicroscopy revealed that CTX shrank ice crystal radii from 37.4 μm to 11.9 μm and slashed the melting enthalpy upon rewarming from 19.99 J/g to 0.28 J/g—confirming no compromise in ice suppression.
One-Step Unloading Solution (ULS): The traditional multi-step unloading process (~60 min) was compressed into a swift 15-minute protocol, minimizing cellular exposure during washout. Optimization boosted the adhesion rate of Human Umbilical Vein Endothelial Cells (HUVECs) from a paltry 8.3% to a robust 88.6%.
Mechanistically, the study identifies the stability of the nuclear lamina protein Lamin B1 as the linchpin resisting osmotic shock. Conventional VS55 treatment markedly weakened Lamin B1's nuclear localization signal, whereas CTX-RYST preserved its normal distribution. Overexpression of Lamin B1 enhanced tolerance, while knockdown exacerbated DNA damage. This discovery advances the understanding of cryoprotectant injury from "cellular membrane osmolarity" to "nuclear mechanical homeostasis," offering a fresh molecular target for rational cryoprotectant design.
Functional Validation: From Bench to Bedside
At the tissue and animal levels, the team established a "nuclear morphology fingerprint" based on nuclear area distribution to quantitatively distinguish between ice injury and solution injury. Results showed that traditional groups exhibited classic solution damage signatures, whereas the CTX-RYST group mirrored fresh controls. Functionally, preserved arterial rings retained the capacity to form microvascular-like structures ex vivo, with intact endothelial and smooth muscle cells. Mechanical tests confirmed that stress relaxation and creep parameters were statistically indistinguishable from fresh arteries, averting the tissue stiffening typical of conventional preservation.
Most crucially, in the rat carotid artery transplantation model, 42-day follow-up data were striking: the stenosis incidence in the CTX-RYST group plummeted to 14% (vs. 86% in controls), with histological narrowing at just 3.5%±4.1% (vs. 24.3%±13.3% in controls). Doppler ultrasound further corroborated stable hemodynamics throughout the observation period.
The team cautions that while promising, these findings are currently limited to rat models and a 42-day timeframe; validation in large animals is essential for clinical translation. Nevertheless, the core value lies in upgrading the optimization framework from a simple trade-off between "ice suppression vs. low toxicity" to a systematic engineering approach encompassing "ice suppression, toxin resistance, and unloading mitigation." It extends evaluation endpoints to nuclear envelope stability, tissue viscoelasticity, and post-transplant functionality. This work establishes a quantifiable experimental paradigm and a new technical starting point for the low-toxicity vitrification of viable vascular and complex tissues.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
